SCHEMBL4164301

SCHEMBL4164301

CC(=O)OCSc1ccc(-c2nc3c(cnn3-c3ccccc3)c(=O)n2-c2ccc(Cl)cc2)cc1

nearest known ligand 0.61

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.61
GRM1 Q13255 6/20 0.57
GRM5 P41594 1/20 0.57
TP53 P04637 3/20 0.57
SMN1; SMN2 Q16637 3/20 0.54
HPGD P15428 2/20 0.54
ALDH1A1 P00352 1/20 0.54
KMT2A Q03164 1/20 0.54
THRB P10828 1/20 0.52
KDR P35968 1/20 0.51
TSHR P16473 3/20 0.48
HTT P42858 3/20 0.48
LMNA P02545 2/20 0.48
ABL1 P00519 1/20 0.48
XBP1 P17861 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13651646 0.87 MAPT (0.55) MAPTGRM1GRM5TP53SMN1; SMN2
SCHEMBL4173004 0.84 MAPT (0.60) MAPTGRM1GRM5TP53SMN1; SMN2
SCHEMBL4161840 0.84 MAPT (0.71) MAPTGRM1GRM5TP53SMN1; SMN2
SCHEMBL1753380 0.83 MAPT (0.80) MAPTGRM1GRM5TP53SMN1; SMN2
SCHEMBL1753030 0.83 MAPT (0.70) MAPTGRM1GRM5TP53SMN1; SMN2
SCHEMBL1689346 0.82 MAPT (0.65) MAPTGRM1GRM5TP53SMN1; SMN2
SCHEMBL1689149 0.82 MAPT (0.78) MAPTGRM1GRM5TP53SMN1; SMN2
SCHEMBL1753259 0.81 TP53 (0.82) MAPTGRM1GRM5TP53SMN1; SMN2
SCHEMBL2116103 0.81 TP53 (0.82) MAPTGRM1GRM5TP53SMN1; SMN2
SCHEMBL1753279 0.81 MAPT (0.80) MAPTGRM1GRM5TP53SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722691-B2 Azolopyrimidines as inhibitors of cannabinoid 1 activity IRM LLC (BM) 2014-05-13 US disclosed
US-8722691-B2 Azolopyrimidines as inhibitors of cannabinoid 1 activity IRM LLC (BM) 2014-05-13 US disclosed
US-8722691-B2 Azolopyrimidines as inhibitors of cannabinoid 1 activity IRM LLC (BM) 2014-05-13 US disclosed
EP-1999132-B1 AZOLOPYRIMIDINES AS INHIBITORS OF CANNABINOID 1 ACTIVITY IRM LLC (BM) 2012-07-18 EP disclosed
US-20090247556-A1 Azolopyrimidines as Inhibitors of Cannabinoid 1 Activity IRM LLC (BM) 2009-10-01 US disclosed
US-20090247556-A1 Azolopyrimidines as Inhibitors of Cannabinoid 1 Activity IRM LLC (BM) 2009-10-01 US disclosed
US-20090247556-A1 Azolopyrimidines as Inhibitors of Cannabinoid 1 Activity IRM LLC (BM) 2009-10-01 US disclosed
EP-1999132-A1 AZOLOPYRIMIDINES AS INHIBITORS OF CANNABINOID 1 ACTIVITY IRM, LLC (BM) 2008-12-10 EP disclosed
WO-2007120454-A1 AZOLOPYRIMIDINES AS INHIBITORS OF CANNABINOID 1 ACTIVITY IRM LLC (BM) 2007-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247556-A1 Azolopyrimidines as Inhibitors of Cannabinoid 1 Activity CNR1, CNR2, ITPR2 MAPT 2577/4885GRM1 424/4885GRM5 118/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.